YICHANG, China – October 20, 2025 – Yichang Tianrui Biopharm Co., Ltd., a wholly-owned subsidiary of Humanwell Group, successfully exhibited at the prestigious Jinan Pharma Partnering Forum, held at the Sheraton Jinan Hotel on October 16-17, 2025. The event served as a dynamic platform for the company to strengthen its market presence and engage with key players in the pharmaceutical industry.

Building on the global leadership of its parent company, Humanwell, in anesthesia and analgesia, Yichang Tianrui Biopharm presented its comprehensive portfolio and advanced technical capabilities to a wide audience. The exhibition highlighted the company's commitment to becoming a trusted partner in the development and manufacturing of high-quality pharmaceutical ingredients.

A Focus on Advanced Capabilities and Core Products

At its booth, the Yichang Tianrui team engaged in productive discussions with numerous visitors, focusing on its core business areas:

• Specialty APIs: Significant interest was generated in key products such as Samidorphan L-Malate, Maribavir, Letermovir, and Lumateperone Tosylate.
• Veterinary APIs: The company's portfolio, including Tiletamine Hydrochloride and Alfaxalone, attracted attention from manufacturers in the animal health sector.
• CDMO/CMO Services: The company's tailored services for High Potency APIs (HPAPIs) and products requiring specialized technologies like high-pressure hydrogenation and lyophilization were a key point of discussion for many seeking reliable manufacturing partners.

Solid Infrastructure as a Foundation for Trust

A central theme of the conversations was the company's solid manufacturing foundation. Attendees were impressed by the scale of the company's investment—a total of $277 million in its modern facility located in the Baiyang Bio-industrial Park. The successful completion of Phase I, with a $112 million investment encompassing 2 international cGMP workshops and 9 dedicated production lines, was presented as a testament to the company's commitment to robust, scalable, and compliant manufacturing.

"The Jinan Pharma Partnering Forum was an excellent opportunity for us to connect with the industry and demonstrate how Yichang Tianrui Biopharm is poised to meet the growing demand for complex APIs and reliable CDMO services," said a company representative. "The positive feedback and high-quality leads we generated confirm the strong market need for a partner with our technical expertise, rigorous quality standards, and substantial manufacturing infrastructure."

The successful participation in this forum underscores Yichang Tianrui Biopharm's active and strategic approach to engaging with the global pharmaceutical community. The company is keen to build upon the connections made and discussions initiated at the event to foster new, long-term partnerships.

About Yichang Tianrui Biopharm Co., Ltd.

Yichang Tianrui Biopharm Co., Ltd., a wholly-owned subsidiary of Humanwell Group, specializes in the R&D, production, and sales of specialty active pharmaceutical ingredients (APIs). Leveraging Humanwell’s global leadership, the company has established a modern manufacturing system compliant with international cGMP standards, equipped with advanced technical platforms including high-pressure hydrogenation, lyophilization, and spray drying. Its core business covers specialty APIs, pharmaceutical intermediates, veterinary APIs, and offers customized development and manufacturing services (CDMO/CMO) for high potency APIs (HPAPIs) and products requiring specialized processes.

Established in 2022, Yichang Tianrui is located in the Baiyang Bio-industrial Park, Yichang High-Tech Development Zone. To strengthen the foundation for specialty API manufacturing, the company has invested a total of $277 million, with a planned layout of 13 international-standard GMP workshops. Phase I has been successfully completed, providing a solid infrastructure for the consistent delivery of high-quality pharmaceutical ingredients.

For more information, please contact:
Business Development
Yichang Tianrui Biopharm Co., Ltd.
Email: ivyzhou@renfu.com.cn

Website: en.yctr.com.cn